MAPT and Cognitive impairment: Surprisingly, using the same animal model it has also been reported that mHFD (42% fat) only applied during gestation protects from synaptic dysfunctions and associated cognitive disorders and decreases Tau and amyloid pathology by reducing the amount Aβ40 and Aβ42.